All In Biotech

Drug Trial Radar · NCT07621237

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jun 25, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Tonix Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests

Conditions

  • Major Depressive Episode (MDE)
  • Major Depressive Disorder (MDD)
  • Depression

Interventions

  • TNX-102 SLDrug

    Participants will take 5.6 mg of TNX-102 SL ( 2 x 2.8 mg TNX-102 SL tablets) daily at bedtime.

  • Placebo sublingual tabletDrug

    Participants will take placebo ( 2 x placebo sublingual tablets) daily at bedtime.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline (Visit 2) in the MADRS total score at Week 6.Time frame: From Day 1 to Week 6

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Phoenix, Arizona · Recruiting

  • Clinical Research Site

    Buena Park, California · Recruiting

  • Clinical Research Site

    Chino, California · Recruiting

  • Clinical Research Site

    Lemon Grove, California · Recruiting

  • Clinical Research Site

    Orange, California · Recruiting

  • Clinical Research Site

    San Diego, California · Recruiting

  • Clinical Research Site

    Walnut Creek, California · Recruiting

  • Clinical Research Site

    Jacksonville, Florida · Recruiting

  • Clinical Research Site

    Maitland, Florida · Recruiting

  • Clinical Research Site

    Miami, Florida · Recruiting

  • Clinical Research Site

    Orange City, Florida · Recruiting

  • Clinical Research Site

    Orlando, Florida · Recruiting

  • Clinical Research Site

    Tampa, Florida · Recruiting

  • Clinical Research Site

    Norcross, Georgia · Recruiting

  • Clinical Research Site

    Chicago, Illinois · Recruiting

  • Clinical Research Site

    New Orleans, Louisiana · Withdrawn

  • Clinical Research Site

    Rockville, Maryland · Recruiting

  • Clinical Research Site

    Methuen, Massachusetts · Recruiting

  • Clinical Research Site

    Las Vegas, Nevada · Recruiting

  • Clinical Research Site

    New York, New York · Recruiting

  • Clinical Research Site

    North Charleston, South Carolina · Recruiting

  • Clinical Research Site

    Mephis, Tennessee · Recruiting

  • Clinical Research Site

    Austin, Texas · Recruiting

  • Clinical Research Site

    Dallas, Texas · Recruiting

  • Clinical Research Site

    McKinney, Texas · Recruiting

  • Clinical Research Site

    Plano, Texas · Recruiting

  • Clinical Research Site

    Provo, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.